1. Home
  2. MXCT vs NGEN Comparison

MXCT vs NGEN Comparison

Compare MXCT & NGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MaxCyte Inc.

MXCT

MaxCyte Inc.

SELL

Current Price

$1.38

Market Cap

155.8M

Sector

Health Care

ML Signal

SELL

Logo NervGen Pharma Corp. Common stock

NGEN

NervGen Pharma Corp. Common stock

SELL

Current Price

$1.86

Market Cap

175.3M

Sector

N/A

ML Signal

SELL

Company Overview

Basic Information
Metric
MXCT
NGEN
Founded
1999
2017
Country
United States
Canada
Employees
N/A
N/A
Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
155.8M
175.3M
IPO Year
2021
2018

Fundamental Metrics

Financial Performance
Metric
MXCT
NGEN
Price
$1.38
$1.86
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
6
6
Target Price
$4.11
★ $8.00
AVG Volume (30 Days)
★ 1.4M
703.7K
Earning Date
11-10-2026
11-16-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
★ $33,026,000.00
N/A
Revenue This Year
$4.77
N/A
Revenue Next Year
$10.06
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$0.64
$1.28
52 Week High
$1.80
$5.97

Technical Indicators

Market Signals
Indicator
MXCT
NGEN
Relative Strength Index (RSI) 55.07 61.82
Support Level $1.02 $1.85
Resistance Level $1.54 $2.32
Average True Range (ATR) 0.14 0.16
MACD -0.01 0.07
Stochastic Oscillator 70.41 72.34

Price Performance

Historical Comparison
MXCT
NGEN

About MXCT MaxCyte Inc.

MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.

About NGEN NervGen Pharma Corp. Common stock

NervGen Pharma Corp is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other traumatic and neurologic conditions. The Company's principal business activity is the discovery, development and commercialization of neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. NervGen's initial target indication is SCI. The company's pipeline products include NVG-291 and NVG-300.

Share on Social Networks: